Clinical Trial Update: Safety and Efficacy of Autologous Human Schwann Cell (ahSC) Augmentation in Severe Peripheral Nerve Injury (PNI) [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating the safety and potential efficacy of autologous human Schwann cell (ahSC) augmentation for severe peripheral nerve injury. The stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Nerve Injury

Drugs mentioned

• Autologous Human Schwann Cell (ahSC) augmentation

Snippet

Sponsor: W. Dalton Dietrich | Conditions: Peripheral Nerve Injury | Phase 1 | Status: RECRUITING